<DOC>
	<DOC>NCT02562807</DOC>
	<brief_summary>The purpose of this study is to evaluate pharmacological effect, safety and pharmacokinetic of TAS-303 in female patients with Stress Urinary Incontinence.</brief_summary>
	<brief_title>A Study of TAS-303 in Female Patients With Stress Urinary Incontinence</brief_title>
	<detailed_description>This study is double-blind, placebo-controlled crossover study. The main purpose of this study is to evaluate Urethral Pressure Profile Parameters in Stress Urinary Incontinence patients who will receive single dose of TAS-303 or Placebo.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<criteria>Key Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior to study entry Patient weights at least 45 kg and has body mass index (BMI) range of 18.030.0 kg/m2, inclusive, at screening Patient is positive in 1hour pad weight test at screening Patient has at least 2 incontinence episodes per week. Key Patient has predominant or primary urge incontinence according to investigator judgment Patient had a prior surgical SUI treatment Patient is diagnosed Pelvic Organ Prolapse Patient is currently taking medication, or has taken medication in the last 4 weeks, for urinary incontinence or that effect urinary output function including anticholinergic or antihistamines or any antianxiety medications. Patient is positive pregnancy test</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Urinary Incontinence, Stress</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
</DOC>